LEADER 01177nam0 2200349 450 001 000020366 005 20081204171927.0 010 $a88-06-05560-7 010 $a88-06-55608-8 100 $a20081204d1983----km-y0itay50------ba 101 1 $aita$crus 102 $aIT 105 $ay-------001yy 200 1 $a<>categorie della cultura medievale$fA. Ja. Gurevic 210 $aTorino$cG. Einaudi$d[1983] 215 $aVIII, 328 p.$d21 cm 225 2 $aEinaudi paperbacks$v143 300 $aTrad. di Clara Castelli 410 0$12001$aEinaudi paperbacks 500 10$aKategorii srednevekovoj kul'tury$m$914402 610 1 $aCultura$aMedioevo 610 1 $aSocietà$aEuropa$aMedioevo 610 1 $aEuropa$aCiviltà$aMedioevo 676 $a909$v18$9Storia medievale e moderna 676 $a940.1$v19$9Storia generale dell'Europa. Dalle origini al 1453 676 $a306.0902$v21$9Cultura e istituzioni. 500-1499 700 1$aGurevic,$bAron Jakovlevic$044678 801 0$aIT$bUNIPARTHENOPE$c20081204$gRICA$2UNIMARC 912 $a000020366 951 $a212.1/103$b3554$cNAVA2 996 $aKategorii srednevekovoj kul'tury$914402 997 $aUNIPARTHENOPE LEADER 03233nam 2200649Ia 450 001 9910457692103321 005 20200520144314.0 010 $a0-19-174025-X 010 $a0-19-960737-0 010 $a1-283-34833-0 010 $a9786613348333 010 $a0-19-157581-X 035 $a(CKB)2550000000064626 035 $a(EBL)797725 035 $a(OCoLC)763157034 035 $a(SSID)ssj0000555589 035 $a(PQKBManifestationID)12244098 035 $a(PQKBTitleCode)TC0000555589 035 $a(PQKBWorkID)10519626 035 $a(PQKB)10355720 035 $a(MiAaPQ)EBC797725 035 $a(StDuBDS)EDZ0000091506 035 $a(Au-PeEL)EBL797725 035 $a(CaPaEBR)ebr10511371 035 $a(CaONFJC)MIL334833 035 $a(EXLCZ)992550000000064626 100 $a20100924d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aSystemic treatment of prostate cancer$b[electronic resource] /$fedited by Alan Horwich 210 $aOxford ;$aNew York $cOxford University Press$d2010 215 $a1 online resource (102 p.) 225 1 $aOxford oncology library 300 $aDescription based upon print version of record. 311 $a0-19-956142-7 320 $aIncludes bibliographical references and index. 327 $aContents; Preface; Symbols and abbreviations; Contributors; 1 Biological principles of hormone therapy; 2 PSA as a marker of progression and response in advanced prostate cancer; 3 Neo-adjuvant and adjuvant hormone therapy for high-risk localized prostate cancer; 4 Systemic treatment of recurrence after local therapies; 5 First-line hormone therapy for metastatic prostate cancer; 6 Second- and third-line hormone therapies; 7 Chemotherapy for metastatic prostate cancer; 8 The role of bisphosphonates in the systemic treatment of prostate cancer; 9 Systemic isotope therapy of bone metastasis 327 $a10 Biological targets and new drug development for prostate cancerIndex; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; R; S; T; U; V; W; Z 330 $aProstate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long been the mainstay ofendocrine therapy in this group of patients, though anti-androgens, oestrogens and corticosteroids can also cause r 410 0$aOxford oncology library. 606 $aProstate$xCancer$xDiagnosis 606 $aProstate$xCancer$xTreatment 608 $aElectronic books. 615 0$aProstate$xCancer$xDiagnosis. 615 0$aProstate$xCancer$xTreatment. 676 $a616.9946306 701 $aHorwich$b Alan$0939780 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910457692103321 996 $aSystemic treatment of prostate cancer$92118828 997 $aUNINA